Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Accounts Payables (2023 - 2025)

Historic Accounts Payables for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $12.3 million.

  • Tonix Pharmaceuticals Holding's Accounts Payables rose 5129.43% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 5129.43%. This contributed to the annual value of $10.7 million for FY2024, which is 1454.09% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Accounts Payables stood at $12.3 million for Q3 2025, which was up 5129.43% from $11.1 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Accounts Payables high stood at $12.5 million for Q4 2023, and its period low was $7.7 million during Q1 2025.
  • Moreover, its 3-year median value for Accounts Payables was $10.4 million (2024), whereas its average is $10.1 million.
  • Data for Tonix Pharmaceuticals Holding's Accounts Payables shows a peak YoY increase of 5129.43% (in 2025) and a maximum YoY decrease of 2809.09% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Accounts Payables stood at $12.5 million in 2023, then fell by 14.54% to $10.7 million in 2024, then increased by 15.61% to $12.3 million in 2025.
  • Its Accounts Payables stands at $12.3 million for Q3 2025, versus $11.1 million for Q2 2025 and $7.7 million for Q1 2025.